Compare Genuine Parts Company (GPC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Organon & Co. Common Stock — how do they compare? Genuine Parts Company trades at $131.49 (market cap $18.02B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Genuine Parts Company is far larger — about 5× Organon & Co. Common Stock's market cap, and Genuine Parts Company pays the higher dividend (3.25%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Organon & Co. Common Stock for 0 Days on average.
| GPC | OGN | |
|---|---|---|
Market Cap | $18.02B | $3.62B |
Volume | 744,000 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $13.81 |
52-Week Low | $92.47 | $5.70 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.11B | $11.04B |
Dividend Yield | 3.25% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $131.63, up 1.55% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss, while net income margin remains thin at 0.13%. The company is progressing with its planned separation into automotive and industrial businesses by Q1 2027, a key strategic move highlighted in recent news.
The outlook is cautiously optimistic, supported by the corporate split catalyst and steady revenue growth, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though valuation metrics like a high P/E of 522.84 warrant attention for potential investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
